Opioids and the Criminal Justice System: New Challenges Posed by the Modern Opioid Epidemic

Literature Cited

1. Agar M, Schacht Reisinger H 2002. A tale of two policies: the French connection, methadone, and heroin epidemics. Cult. Med. Psychiatry 26:3371–96
   [Google Scholar]
2. Alexander M. 2011. The new Jim Crow. Ohio St. J. Crim. L. 9:7
   [Google Scholar]
3. Alpert A, Powell D, Pacula RL 2018. Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids. Am. Econ. J. Econ. Policy. 10:41–35
   [Google Scholar]
4. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP 2005. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 28:4321–29
   [Google Scholar]
5. Anderson JF. 2001. What to do about “much ado” about drug courts. Int. J. Drug Policy 12:5469–75
   [Google Scholar]
6. Anglin MD, Brecht ML, Maddahian E 1989. Pretreatment characteristics and treatment performance of legally coerced versus voluntary methadone maintenance admissions. Criminology 27:3537–57
   [Google Scholar]
7. Aos S, Miller M, Drake E 2006. Evidence-based public policy options to reduce future prison construction, criminal justice costs, and crime rates Rep., Wash. State Inst. Public Policy Olympia: https://www.wsipp.wa.gov/ReportFile/952/Wsipp_Evidence-Based-Public-Policy-Options-to-Reduce-Future-Prison-Construction-Criminal-Justice-Costs-and-Crime-Rates_Full-Report.pdf
   [Google Scholar]
8. Armstrong D. 2019. Purdue's Sackler embraced plan to conceal OxyContin's strength from doctors, sealed deposition shows. ProPublica Feb. 21. https://www.propublica.org/article/richard-sackler-oxycontin-oxycodone-strength-conceal-from-doctors-sealed-testimony
   [Google Scholar]
9. Babor TF, Caulkins JP, Edwards G, Fischer B, Foxcroft DR et al. 2018. Drug Policy and the Public Good New York: Oxford Univ. Press, 2nd ed..
10. Ball JC, Rosen L, Flueck JA, Nurco DN 1982. Lifetime criminality of heroin addicts in the United States. J. Drug Issues. 12:3225–39
    [Google Scholar]
11. Becker G, Murphy K, Grossman M 2006. The market for illegal goods: the case of drugs. J. Political Econ. 114:138–60
    [Google Scholar]
12. Belenko S. 2001. Research on drug courts: a critical review, 2001 update Natl. Cent. Addict. Subst. Abuse Rep., Columbia Univ New York:
    [Google Scholar]
13. Bhati AS, Roman JK, Chalfin A 2008. To treat or not to treat: evidence on the prospects of expanding treatment to drug-involved offenders Justice Policy Cent. Rep. NCJ 222908, Urban Inst Washington, DC: https://www.ncjrs.gov/pdffiles1/nij/grants/222908.pdf
    [Google Scholar]
14. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A et al. 2007. Release from prison: a high risk of death for former inmates. New Engl. J. Med. 356:2157–65
    [Google Scholar]
15. Bird SM, McAuley A, Perry S, Hunter C 2016. Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006–10) versus after (2011–13) comparison. Addiction 111:5883–91
    [Google Scholar]
16. Blumstein A, Cork D. 1996. Linking gun availability to youth gun violence. Law Contemp. Probl. 59:15–24
    [Google Scholar]
17. Boyer EW. 2012. Management of opioid analgesic overdose. N. Engl. J. Med. 367:2146–55
    [Google Scholar]
18. Brecht ML, Anglin MD, Wang JC 1993. Treatment effectiveness for legally coerced versus voluntary methadone maintenance clients. Am. J. Drug Alcohol Abuse 19:189–106
    [Google Scholar]
19. Bronson J, Stroop J, Zimmer S, Berzofsky M 2017. Drug use, dependence, and abuse among state prisoners and jail inmates. 2007–2009 Bur. Justice Stat. Rep. NCJ 250546, Dep. Justice Washington, DC: https://www.bjs.gov/content/pub/pdf/dudaspji0709.pdf
    [Google Scholar]
20. Caulkins JP, Kilmer B, Reuter PH, Midgette G 2015. Cocaine's fall and marijuana's rise: questions and insights based on new estimates of consumption and expenditures in US drug markets. Addiction 110:5728–36
    [Google Scholar]
21. Caulkins JP, Reuter P. 2010. How drug enforcement affects drug prices. Crime Justice 39:1213–71
    [Google Scholar]
22. Chilvers M, Weatherburn D. 2003. The impact of heroin dependence on long-term robbery trends Crime Justice Bull. Rep. 79, NSW Bur. Crime Res. Stat Sydney: https://pdfs.semanticscholar.org/dca2/623fe7bb748f8ccd7d4c123f32d1794dc130.pdf
23. Cicero TJ, Ellis MS, Surratt HL 2012. Effect of abuse-deterrent formulation of OxyContin. New Engl. J. Med. 367:2187–89
    [Google Scholar]
24. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP 2014. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71:7821–26
    [Google Scholar]
25. Compton WM, Jones CM, Baldwin GT 2016. Relationship between nonmedical prescription-opioid use and heroin use. New Engl. J. Med. 374:2154–63
    [Google Scholar]
26. Dagan D, Teles SM. 2012. The conservative war on prisons. Washington Monthly Novemb./Dec. https://washingtonmonthly.com/magazine/novdec-2012/the-conservative-war-on-prisons/
    [Google Scholar]
27. Davis CS, Carr DH. 2017. Self-regulating profession? Administrative discipline of “pill mill” physicians in Florida. Subst. Abuse 38:3265–68
    [Google Scholar]
28. Degenhardt L, Conroy E, Gilmour S, Collins L 2005a. The effect of a reduction in heroin supply in Australia upon drug distribution and acquisitive crime. Br. J. Criminol. 45:2–224
    [Google Scholar]
29. Degenhardt L, Day C, Dietze P, Pointer S, Conroy E et al. 2005b. Effects of a sustained heroin shortage in three Australian States. Addiction 100:908–20
    [Google Scholar]
30. Degenhardt L, Reuter P, Collins L, Hall W 2005c. Evaluating explanations of the Australian ‘heroin shortage. .’ Addiction 100:4459–69
    [Google Scholar]
31. Delcher C, Wagenaar AC, Goldberger BA, Cook RL, Maldonado-Molina MM 2015. Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug Alcohol Depend 150:63–68
    [Google Scholar]
32. D'Hotman D, Pugh J, Douglas T 2018. When is coercive methadone therapy justified. Bioethics 32:7405–13
    [Google Scholar]
33. Dowell D, Haegerich TM, Chou R 2016. CDC guideline for prescribing opioids for chronic pain—United States. JAMA 315:151624–45
    [Google Scholar]
34. Drucker E. 2002. Population impact of mass incarceration under New York's Rockefeller drug laws: an analysis of years of life lost. J. Urban Health 79:3434–35
    [Google Scholar]
35. Drug Enforc. Adm. (DEA). 2019. National drug threat assessment Rep. DEA-DCT-DIR-007-20, Dep. Justice Washington, DC: https://www.dea.gov/sites/default/files/2020-01/2019-NDTA-final-01-14-2020_Low_Web-DIR-007-20_2019.pdf
36. Dyer O. 2015. Murder trials begin in US against two high opioid prescribers. BMJ 351:h4827
    [Google Scholar]
37. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD 2014. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain: the role of opioid prescription. Clin. J. Pain 30:7557–64
    [Google Scholar]
38. Engberg J, Morral AR. 2006. Reducing substance use improves adolescents’ school attendance. Addiction 101:121741–51
    [Google Scholar]
39. Estelle v. Gamble 429 U.S. 97 1976.)
40. Evans WN, Lieber EM, Power P 2019. How the reformulation of OxyContin ignited the heroin epidemic. Rev. Econ. Stat. 101:11–15
    [Google Scholar]
41. Farabee D, Prendergast M, Anglin MD 1998. The effectiveness of coerced treatment for drug-abusing offenders. Fed. Probat. 62:3–10
    [Google Scholar]
42. Farabee D, Prendergast M, Cartier J, Wexler H, Knight K, Anglin MD 1999. Barriers to implementing effective correctional drug treatment programs. Prison J 79:2150–62
    [Google Scholar]
43. Felbab-Brown V. 2019. Mexico's out-of-control criminal market in foreign policy Rep., Brookings Washington, DC: https://www.brookings.edu/wp-content/uploads/2019/03/FP_20190322_mexico_crime-2.pdf
44. Forman J Jr 2012. Racial critiques of mass incarceration: beyond the new Jim Crow. NYU Law Rev 87:101–46
    [Google Scholar]
45. Gandossy RP, Williams JR, Cohen J, Harwood HJ 1980. Drugs and crime: a survey and analysis of the literature Natl. Inst. Justice Rep. NCJ 159074, Dep. Justice Washington, DC:
    [Google Scholar]
46. Gau JM, Brooke EJ. 2017. An assessment of the impact of a multipronged approach to reducing problematic pain clinics in Florida. J. Drug Issues 47:2185–204
    [Google Scholar]
47. Gerstein DR, Johnson RA, Harwood HJ, Fountain D, Suter N, Malloy K 1994. Evaluating recovery services: the California drug and alcohol treatment assessment CalDATA general report submitted to the State of California, Department of Alcohol and Drug Programs Rep., Calif. Dep. Alcohol Drug Progr Sacramento:
    [Google Scholar]
48. Goldkamp JS, White MD, Robinson JB 2001. Do drug courts work? Getting inside the drug court black box. J. Drug Issues 31:127–72
    [Google Scholar]
49. Goldstein PJ. 1985. The drugs/violence nexus: a tripartite conceptual framework. J. Drug Issues 15:4493–506
    [Google Scholar]
50. Goldstein PJ, Brownstein HH, Ryan PJ, Bellucci PA 1989. Crack and homicide in New York City, 1988: a conceptually based event analysis. Contemp. Drug Probl. 16:4651–87
    [Google Scholar]
51. Green DP, Winik D. 2010. Using random judge assignments to estimate the effects of incarceration and probation on recidivism among drug offenders. Criminology 48:2357–87
    [Google Scholar]
52. Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BDL, Alexander-Scott N et al. 2018. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry 75:4405–7
    [Google Scholar]
53. Hall W, Ward J, Mattick R 1993. Methadone maintenance treatment in prisons: the New South Wales experience. Drug Alcohol Rev 12:2193–203
    [Google Scholar]
54. Hamilton Z, Campbell CM, Van Wormer J, Kigerl A, Posey B 2016. Impact of swift and certain sanctions: evaluation of Washington State's policy for offenders on community supervision. Criminol. Public Policy 15:1009–72
    [Google Scholar]
55. Hammersley R, Forsyth A, Morrison V, Davies JB 1989. The relationship between crime and opioid use. Addiction 9:1029–43
    [Google Scholar]
56. Hawken A. 2018. Economic implications of HOPE from the demonstration field experiment. Criminol. Public Policy 17:4901–6
    [Google Scholar]
57. Hawken A, Kleiman M. 2009. Managing drug involved probationers with swift and certain sanctions: evaluating Hawaii's HOPE Rep. NCJ 229023, Natl. Inst. Justice Washington, DC:
    [Google Scholar]
58. Hawley M. 2002. Heroin shortage: the cause. Platypus Mag 76:43–48
    [Google Scholar]
59. Hedrich D, Alves P, Farrel M, Stöver H, Møller L, Mayet S 2012. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 107:3501–17
    [Google Scholar]
60. Hser YI, Teruya C, Brown AH, Huang D, Evans E, Anglin MD 2007. Impact of California's Proposition 36 on the drug treatment system: treatment capacity and displacement. Am. J. Public Health 97:1104–9
    [Google Scholar]
61. Holloway KR, Bennett TH, Farrington DP 2006. The effectiveness of drug treatment programs in reducing criminal behavior: a meta-analysis. Psicothema 18:3620–29
    [Google Scholar]
62. Humphreys K. 2017. Avoiding globalisation of the prescription opioid epidemic. Lancet 390:10093437–39
    [Google Scholar]
63. Inciardi JA, McBride DC. 1994. Treatment Alternatives to Street Crime Darby, PA: Diane Publ.
64. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ 2007a. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 8:2171–83
    [Google Scholar]
65. Inciardi JA, Surratt HL, Lugo Y, Cicero TJ 2007b. The diversion of prescription opioid analgesics. Law Enforc. Executive Forum 7:7127–41
    [Google Scholar]
66. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA et al. 2018. Extended‐release injectable naltrexone for opioid use disorder: a systematic review. Addiction 113:71188–209
    [Google Scholar]
67. Johnson BD, Goldstein PJ, Preble E, Schmeidler J, Lipton DS et al. 1985. Taking Care of Business: The Economics of Crime by Heroin Abusers Lexington, MA: Lexington Books
    [Google Scholar]
68. Kaplan J. 1983. The Hardest Drug: Heroin and Public Policy Chicago: Univ. Chicago Press
    [Google Scholar]
69. Kelly SM, O'Grady KE, Jaffe JH, Gandhi D, Schwartz RP 2013. Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment. J. Addict. Med. 7:2133–38
    [Google Scholar]
70. Kennedy DM. 2009. Deterrence and Crime Prevention: Reconsidering the Prospect of Sanction New York: Routledge
    [Google Scholar]
71. Kennedy-Hendricks A, Richey M, McGinty EE, Stuart EA, Barry CL, Webster DW 2016. Opioid overdose deaths and Florida's crackdown on pill mills. Am. J. Public Health 106:2291–97
    [Google Scholar]
72. Kiang MV, Humphreys K, Cullen MR, Basu S 2020. Opioid prescribing patterns among medical providers in the United States, 2003–17: retrospective, observational study. BMJ 368:16968
    [Google Scholar]
73. Kilmer B, Nicosia N, Heaton P, Midgette G 2013. Efficacy of frequent monitoring with swift, certain, and modest sanctions for violations: insights from South Dakota's 24/7 Sobriety Project. Am. J. Public Health 103:1e37–43
    [Google Scholar]
74. Kilmer B, Reuter P. 2009. Prime numbers: doped. Foreign Policy Oct. 16. https://foreignpolicy.com/2009/10/16/prime-numbers-doped/
    [Google Scholar]
75. King RS, Pasquarella J. 2009. Drug courts: a review of the evidence Rep., Sentencing Proj Washington, DC: https://www.sentencingproject.org/publications/drug-courts-a-review-of-the-evidence/
    [Google Scholar]
76. Klag S, O'Callaghan F, Creed P 2005. The use of legal coercion in the treatment of substance abusers: an overview and critical analysis of thirty years of research. Subst. Use Misuse 40:121777–95
    [Google Scholar]
77. Kleiman MAR 1994. Against Excess: Drug Policy for Results New York: Basic Books
    [Google Scholar]
78. Kleiman MAR 2009. When Brute Force Fails: How to Have Less Crime and Less Punishment Princeton, NJ: Princeton Univ. Press
    [Google Scholar]
79. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL et al. 2015. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu. Rev. Public Health 36:559–74
    [Google Scholar]
80. Kuchler H, Verbitsky N, Jennings T, Connaire S 2020. Insys executives are sentenced to prison time, putting opioid makers on notice. Financial Times Jan. https://www.pbs.org/wgbh/frontline/article/opioid-maker-insys-executives-sentenced-prison-subsys/
    [Google Scholar]
81. Kuehn BM. 2014. CDC: major disparities in opioid prescribing among states: some states crack down on excess prescribing. JAMA 312:7684–86
    [Google Scholar]
82. Larney S, Dolan K. 2009. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care. Eur. Addict. Res. 15:2107–12
    [Google Scholar]
83. Lattimore PK, MacKenzie DL, Zajac G, Dawes D, Arsenault E, Tueller S 2016. Outcome findings from the HOPE Demonstration Field Experiment: Is swift, certain, and fair an effective supervision strategy. Criminol. Public Policy 15:41103–41
    [Google Scholar]
84. Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL et al. 2018. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391:10118309–18
    [Google Scholar]
85. Linden M, Marullo S, Bone C, Barry DT, Bell K 2018. Prisoners as patients: the opioid epidemic, medication-assisted treatment, and the Eighth Amendment. J. Law Med. Ethics 46:2252–67
    [Google Scholar]
86. Longshore D, Hawken A, Urada D, Anglin MD 2006. Evaluation of the Substance Abuse and Crime Prevention Act: SACPA cost-analysis report (first and second years) Rep., UCLA Integr. Subst. Abuse Progr Los Angeles: http://www.uclaisap.org/prop36/documents/sacpa_costanalysis.pdf
    [Google Scholar]
87. Ludwig AS, Peters RH. 2014. Medication-assisted treatment for opioid use disorders in correctional settings: an ethics review. Int. J. Drug Policy 25:61041–46
    [Google Scholar]
88. Maradiaga JA, Nahvi S, Cunningham CO, Sanchez J, Fox AD 2016. “I kicked the hard way. I got incarcerated.” Withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. J. Subst. Abuse Treat. 62:49–54
    [Google Scholar]
89. Marlowe DB, Merikle EP, Kirby KC, Festinger DS, McLellan AT 2001. Multidimensional assessment of perceived treatment-entry pressures among substance abusers. Psychol. Addict. Behav. 15:297–198
    [Google Scholar]
90. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D 2014. “Every ‘never’ I ever said came true”: transitions from opioid pills to heroin injecting. Int. J. Drug Policy 25:2257–66
    [Google Scholar]
91. Marsch LA. 1998. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta‐analysis. Addiction 93:4515–32
    [Google Scholar]
92. Massing M. 2000. The Fix Berkeley: Univ. Calif. Press
93. Mattick RP, Breen C, Kimber J, Davoli M 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 3:CD002209
    [Google Scholar]
94. Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM et al. 2013. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J. Subst. Abuse Treat. 44:5473–80
    [Google Scholar]
95. Mauer M. 2006. Race to Incarcerate New York: New Press
96. McDonald R, Strang J. 2016. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 111:71177–87
    [Google Scholar]
97. Meier B. 2007. In guilty plea, Oxycontin maker to pay $600 million. New York Times May 10. https://www.nytimes.com/2007/05/10/business/11drug-web.html
    [Google Scholar]
98. Meier B. 2018. Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic New York: Random House
    [Google Scholar]
99. Midgette G, Davenport S, Caulkins JP, Kilmer B 2019. What America's users spend on illegal drugs, 2006–2016 Rep. RR-3140, RAND Santa Monica, CA:
    [Google Scholar]
100. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A 2011. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 4:CD001333
     [Google Scholar]
101. Mitchell O, Wilson DB, MacKenzie DL 2012. The effectiveness of incarceration-based drug treatment on criminal behavior: a systematic review. Campbell Syst. Rev. 8:11–76
     [Google Scholar]
102. Moore MH. 1973. Policies to achieve discrimination on the effective price of heroin. Am. Econ. Rev. 63:2270–77
     [Google Scholar]
103. Morris N, Tonry M. 1991. Between Prison and Probation: Intermediate Punishments in a Rational Sentencing System New York: Oxford Univ. Press
     [Google Scholar]
104. Muhuri PK, Gfroerer JC, Davies MC 2013. Associations of nonmedical pain reliever use and initiation of heroin use in the United States CBHSQ Data Rev Rep., SAMHSA Rockville, MD:
105. Musto DF. 1999. The American Disease: Origins of Narcotic Control New York: Oxford Univ. Press
     [Google Scholar]
106. Natl. Acad. Sci. Eng. Med. 2017. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use Rep., Natl. Acad. Sci. Eng. Med Washington, DC:
     [Google Scholar]
107. Nicosia N, Kilmer B, Heaton P 2016. Can a criminal justice alcohol abstention programme with swift, certain, and modest sanctions (24/7 Sobriety) reduce population mortality? A retrospective observational study. Lancet Psychiatry 3:3226–32
     [Google Scholar]
108. Nordstrom BR, Dackis CA. 2011. Drugs and crime. J. Psychiatry Law 39:4663–87
     [Google Scholar]
109. Nunes EV, Shulman M. 2020. Commentary on Stein et al. (2020): Whither detoxification in the face of the opioid epidemic. Addiction 115:195–96
     [Google Scholar]
110. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD 2009. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend 105:1–283–88
     [Google Scholar]
111. O'Connell DJ, Brent JJ, Visher CA 2016. Decide your time. Criminol. Public Policy 15:41073–102
     [Google Scholar]
112. O'Connor S. 2017. Meth precursor chemicals from China: implications for the United States Rep., US-China Econ. Secur. Rev. Comm Washington, DC: https://www.uscc.gov/sites/default/files/Research/Staff%20Report_PrecursorChemicalReport%20071816_0.pdf
     [Google Scholar]
113. Paoli L, Greenfield VA, Reuter P 2009. The World Heroin Market: Can Supply Be Cut? New York: Oxford Univ. Press
     [Google Scholar]
114. Pardo B, Davis LM, Moore M 2019a. Characterization of the synthetic opioid threat profile to inform inspection and detection solutions Rep., RAND Santa Monica, CA:
115. Pardo B, Reuter P. 2018. Narcotics and drug abuse: foreshadowing of 50 years of change. Criminol. Public Policy 17:2419–36
     [Google Scholar]
116. Pardo B, Taylor J, Caulkins JP, Kilmer B, Reuter P, Stein BD 2019b. The future of fentanyl and other synthetic opioids Rep., RAND Santa Monica, CA:
117. Parker RN, Nash R, Auerhahn K 1998. Alcohol, drugs, and violence. Annu. Rev. Sociol. 24:291–311
     [Google Scholar]
118. Parmar MKB, Strang J, Choo L, Meade AM, Bird SM 2017. Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths. Addiction 112:3502–15
     [Google Scholar]
119. Pfaff JF. 2014. Escaping from the standard story: why the conventional wisdom on prison growth is wrong, and where we can go from here. Fed. Sentencing Rep. 26:4265–70
     [Google Scholar]
120. Pfaff JF. 2017. Locked In: The True Causes of Mass Incarceration and How to Achieve Real Reform New York: Basic Books
     [Google Scholar]
121. Poklis A. 1995. Fentanyl: a review for clinical and analytical toxicologists. J. Toxicol. Clin. Toxicol. 33:5439–47
     [Google Scholar]
122. Pollack H, Reuter P, Sevigny EL 2011. If drug treatment works so well, why are so many drug users in prison? NBER Work. Pap 16731. https://doi.org/10.3386/w16731
     [Crossref] [Google Scholar]
123. Pollack HA, Reuter P. 2014. Does tougher enforcement make drugs more expensive. Addiction 109:121959–66
     [Google Scholar]
124. Powell D, Pacula RL, Taylor E 2020. How increasing medical access to opioids contributes to the opioid epidemic: evidence from Medicare Part D. J. Health Econ. 71:102286
     [Google Scholar]
125. Preble E, Casey J. 1969. Taking care of business: the heroin user's life on the street. Int. J. Addict. 4:1–24
     [Google Scholar]
126. Prendergast ML, Podus D, Chang E, Urada D 2002. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend 67:153–72
     [Google Scholar]
127. Pres. Comm. Law Enforc. Adm. Justice. 1967. The challenge of crime in a free society Rep., Pres. Comm. Law Enforc. Adm. Justice Washington, DC:
128. QuintilesIMS Inst. 2017. United States for non-dependence: an analysis of the impact of opioid overprescribing in America Rep., Pacira Biosci Parsippany, NJ: https://www.planagainstpain.com/wp-content/uploads/2017/09/PlanAgainstPain_USND.pdf
     [Google Scholar]
129. Reuter P. 1984. The (continued) vitality of mythical numbers. Public Interest 75:135–47
     [Google Scholar]
130. Reuter P. 2009. Systemic violence in drug markets. Crime Law Soc. Change 52:3275–84
     [Google Scholar]
131. Reuter P, Kleiman M. 1986. Risks and prices: an economic analysis of drug enforcement. Crime Justice Annu. Rev. Res. 7:289–340
     [Google Scholar]
132. Rigg KK, Kurtz SP, Surratt HL 2012. Patterns of prescription medication diversion among drug dealers. Drugs Educ. Prev. Policy 19:2145–55
     [Google Scholar]
133. Rigg KK, March SJ, Inciardi JA 2010. Prescription drug abuse & diversion: role of the pain clinic. J. Drug Issues 40:3681–701
     [Google Scholar]
134. Rocheleau AM, Boyum D. 1994. Measuring heroin availability in three cities Off. Natl. Drug Control Policy Rep., Executive Off. President Washington, DC:
135. Simeone R. 2017. Doctor shopping behavior and the diversion of prescription opioids. Subst. Abuse Res. Treat. 11:1178221817696077
     [Google Scholar]
136. Smithson M, McFadden M, Mwesigye S, Casey T 2004. The impact of illicit drug supply reduction on health and social outcomes: the heroin shortage in the Australian Capital Territory. Addiction 98:340–48
     [Google Scholar]
137. Spohn C, Holleran D. 2002. The effect of imprisonment on recidivism rates of felony offenders: a focus on drug offenders. Criminology 40:2329–58
     [Google Scholar]
138. Sporer KA, Firestone J, Isaacs SM 1996. Out‐of‐hospital treatment of opioid overdoses in an urban setting. Acad. Emerg. Med. 3:7660–67
     [Google Scholar]
139. Springer SA, Altice FL, Brown SE, Di Paola A 2015. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend 157:158–65
     [Google Scholar]
140. Stallwitz A, Stöver H. 2007. The impact of substitution treatment in prisons: a literature review. Int. J. Drug Policy 18:6464–74
     [Google Scholar]
141. Stein M, Herman D, Conti M, Anderson B, Bailey G 2020. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient ‘detoxification’: a randomized clinical trial. Addiction 115:182–94
     [Google Scholar]
142. Sufrin C, Sutherland L, Beal L, Terplan M, Latkin C, Clarke JG 2020. Opioid use disorder incidence and treatment among incarcerated pregnant people in the US: results from a national surveillance study. Addiction https://doi.org/10.1111/add.15030
     [Crossref] [Google Scholar]
143. Surratt HL, O'Grady C, Kurtz SP, Stivers Y, Cicero TJ et al. 2014. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol. Drug Saf. 23:314–20
     [Google Scholar]
144. Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A et al. 2017. Effectiveness of injectable extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry 74:121197–205
     [Google Scholar]
145. Travis J, Western B, Redburn FS 2014. The Growth of Incarceration in the United States: Exploring Causes and Consequences Washington, DC: Natl. Acad. Press
     [Google Scholar]
146. Wakeman SE. 2017. Why it's inappropriate not to treat incarcerated patients with opioid agonist therapy. AMA J. Ethics 19:9922–93
     [Google Scholar]
147. Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K 2006. Value for money in drug treatment: economic evaluation of prison methadone. Drug Alcohol Depend 84:2160–66
     [Google Scholar]
148. Weisburd D, Braga AA. 2006. Introduction: understanding police innovation. Police Innovation: Contrasting Perspectives D Weisburd, AA Braga 1–23 Cambridge, UK: Cambridge Univ. Press
     [Google Scholar]
149. Werb D, Kamarulzaman A, Meacham M, Rafful C, Fisher B et al. 2016. The effectiveness of compulsory drug treatment: a systematic review. Int. J. Drug Policy 28:1–9
     [Google Scholar]
150. Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL 2020. Drug and opioid-involved overdose deaths—United States, 2017–2018. Morb. Mortal. Wkly. Rep. 69:290–97
     [Google Scholar]
151. Wood E, Stoltz JA, Li K, Montaner JSG, Kerr T 2006. Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction 101:5689–95
     [Google Scholar]
152. Zeng Z. 2019. Jail inmates in 2017 Bur. Justice Stat. Rep. NCJ 251774, Dep. Justice Washington, DC: https://www.bjs.gov/content/pub/pdf/ji17.pdf